Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma.
Jpn J Clin Oncol
; 50(8): 920-925, 2020 Aug 04.
Article
em En
| MEDLINE
| ID: mdl-32463095
ABSTRACT
BACKGROUND:
Limited options exist for treating post-recurrence patients with malignant pleural mesothelioma (MPM). This study aimed to evaluate the efficacy and feasibility of nivolumab in patients with post-operative recurrence of MPM in a real-world setting.METHODS:
This study included 35 patients with post-operative recurrence of MPM. Treatment consisted of 240-mg intravenous nivolumab administration every 2 weeks until progressive disease (PD) or serious adverse events (AEs). Additional post-treatment data were evaluated, including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), post-treatment survival and AEs. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors. Survival analysis was performed using the Kaplan-Meier method. The feasibility analysis including AEs was performed with the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.RESULTS:
Of the 35 patients who received nivolumab, median follow-up was 6 months. The median treatment duration was 3 months (range 1-14 months), and median of 8 cycles (range 2-32 cycles) was administered. Best overall responses were follows 1 patient had complete response, 6 had partial response, 18 had stable disease and 8 had PD. The ORR was 20.0%, and the DCR was 77.1%. The median overall survival and PFS were 13.1 and 4.4 months, respectively. There were grade-3 AEs in four patients (11.4%). No grade-4 or -5 AEs were observed.CONCLUSION:
Nivolumab treatment in patients with post-operative recurrence of MPM seems safe and clinical efficacy.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Nivolumabe
/
Neoplasias Pulmonares
/
Mesotelioma
/
Recidiva Local de Neoplasia
Tipo de estudo:
Evaluation_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article